Carol L. Koski, M.D.

Dr. Carol Lee Koski was educated at Goucher College in Towson, Maryland and University of Maryland School of Medicine.  After completing her medical education, she trained in internal medicine and neurology at University of Maryland Medical Systems and at Jackson Memorial Hospital, University of Miami.  She did subsequent fellowships in Neuromuscular Disease, Neurochemistry and Neuroimmunology at University Hospital in Baltimore, the Eunice Kennedy Shriver Center in Waltham and the Neuroimmunology Branch at the NIH respectively. She was an Assistant Professor of Neurology at Boston University where she directed the Electrophysiology Laboratory and Muscular Dystrophy clinic, following which, she was awarded a Teacher Investigator award from NIH prior to returning to the University of Maryland School of Medicine in 1976. Dr Koski was appointed Director of the Neuromuscular Division in 1993 and Professor of Neurology in 1994 and retired from the University in April of 2006. Her major research interests include the roles of complement in inflammatory neuropathy, ovarian hormones in neuronal survival in CNS inflammation and validation of clinical criteria for chronic inflammatory polyneuritis.  She developed the physicians’ infusion clinic at the University of Maryland. She served on the FDA panel on CNS and PNS drugs and continues to serve currently as a consultant. She is a member of the Medical Advisory Board for the GBS-CIDP Foundation and serves as the medical liaison to both the Board of Directors and Board of Trustees of the GBS-CIDP Foundation International. Some of the projects currently ongoing include epidemiologic validation of CIDP diagnostic criteria and an outcomes survey of CIDP patients to determine therapies used, long term responses, disability and costs.

View complete CV for Dr. Koski (PDF)

Select CIDP Publications by Carol L. Koski, M.D.

Links that appear on this page will cause you to exit this site and go to the PubMed site. These links provide additional information that may be useful or interesting, and is being provided consistent with the intended purpose of the CIDP Information Center. However, as the sponsor of the CIDP Information Center, Talecris Biotherapeutics cannot attest to the accuracy of information provided by this link and assumes no responsibility or liability for the contents provided by this link.

To return to the CIDP Information Center, use the back button in your browser or bookmark this page.

• European Federation of Neurological Societies; Peripheral Nerve Society; Hadden RD, Nobile-Orazio E, Sommer C, Hahn A, Illa I, Morra E, Pollard J, Hughes RA, Bouche P, Cornblath D, Evers E, Koski CL, Leger JM, Van den Bergh P, van Doorn P, van Schaik IN. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2006 ;13(8):809-18.
• European Federation of Neurological Societies; Peripheral Nerve Society; van Schaik IN, Bouche P, Illa I, Leger JM, Van den Bergh P, Cornblath DR, Evers EM, Hadden RD, Hughes RA, Koski CL, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy.Eur J Neurol. 2006 Aug;13(8):802-8.
• Good JL, Cherenama M, Mayer RF, and Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51:1735-8, 1998.
• Koski CL. 2004. Identifying the Benefits of IVIG in Peripheral Neuromuscular Disease. Advances in Immunotherapy. 11:9-14.2004
• Koski CL. 2005. Chronic inflammatory demyelinating polyneuritis. Volume 7, Current Therapy in Neurological Diseases
• David S, Hila S, Fosbrink M, Rus H, and Koski CL. 2005. JNK Activity Mediates C5b-9 induced Po mRNA Instability and Po Gene Expression in Schwann Cells. J Peripher Nerv Syst. 2006 ;11(1):77-87.
• Koski CL. 2005. Initial and Long-Term Management of Autoimmune Neuropathies. 2005;19(12):1033-48. Review.
• Koski CL, Patterson JV. Intravenous immunoglobulin use for neurologic diseases. J Infus Nurs. 2006;29(3 Suppl):S21-8.
• Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, Van den Bergh P, van Doorn PA, van Schaik IN.European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.Eur J Neurol. 2006 ,13(4):326-32.
• Sanders ME, Alexander EL, Koski CL, Shin ML, Sano Y, Frank MM, and Joiner, KA. Terminal Complement complexes (SC5b-9) in Cerebrospinal Fluid in Autoimmune Nervous System Diseases. Annals NY Academy of Sciences 1988, 540:387-389.
• Sorensen R, MD, Dinakar C, Fuleihan R, Gupta S, Knutsen A, Kobayashi R, Koski CL, MD, Levinson A, Shapiro R, Wasserman RL. Clinical and other outcome considerations in the formulary review of Immune globulin. 2007 JMCP, In Review.

To view all publications by Carol L. Koski, visit PubMed.